GLPG3312 is a potent and selective inhibitor of pan-SIK, with an IC50 of 2.0 nM for SIK1, 0.7 nM for SIK2, and 0.6 nM for SIK3. It demonstrates anti-inflammatory and immunoregulatory activities in vitro in human primary myeloid cells and in vivo in mouse models.

GLPG3312 is a potent and selective inhibitor of pan-SIK, with an IC50 of 2.0 nM for SIK1, 0.7 nM for SIK2, and 0.6 nM for SIK3. It demonstrates anti-inflammatory and immunoregulatory activities in vitro in human primary myeloid cells and in vivo in mouse models.

CAY10499 (MAGL-IN-5) is a non-selective lipase inhibitor with IC₅₀ values of 144 nM for human recombinant monoacylglycerol lipase (MAGL), 90 nM for hormone-sensitive lipase (HSL), and 14 nM for fatty acid amide hydrolase (FAAH). It also inhibits cell growth in MCF-7, MB-231, COV318, OVCAR-3 cancer cell lines.

BTTAA is a Cu(I)-stabilizing ligand that enhances CuAAC reaction efficiency. It is highly effective for labeling and detecting azide-tagged glycoconjugates in Jurkat cells, zebrafish, and bacteria.

GLPG3312 is a potent and selective inhibitor of pan-SIK, with an IC50 of 2.0 nM for SIK1, 0.7 nM for SIK2, and 0.6 nM for SIK3. It demonstrates anti-inflammatory and immunoregulatory activities in vitro in human primary myeloid cells and in vivo in mouse models.

Ionomycin calcium (SQ23377 calcium) is a potent and selective calcium ionophore and an antibiotic produced by Streptomyces conglobatus. It is highly specific for divalent cations (Ca>Mg>Sr=Ba) and also promotes T cell activation and proliferation by inducing phosphoinositide hydrolysis and protein kinase C (PKC) activation, leading to IL-2 production and IL-2R expression.

Oxidopamine (6-OHDA) hydrochloride is an antagonist of the neurotransmitter dopamine. Oxidopamine hydrochloride is a widely used neurotoxin and selectively destroys dopaminergic neurons. Oxidopamine hydrochloride promotes COX-2 activation, leading to PGE2 synthesis and pro-inflammatory cytokine IL-1β secretion. Oxidopamine hydrochloride can be used for the research of Parkinson’s disease (PD), attention-deficit hyperactivity disorder (ADHD), and Lesch-Nyhan syndrome.

BAY 2413555 is a first selective positive allosteric modulator of the muscarinic acetylcholine receptor (M2R) to restore cardiac autonomic balance. It also inhibits CYP2C8 and CYP2C9 with IC50 values of 17 µM and 13 µM, respectively.

BAY 2413555 is a first selective positive allosteric modulator of the muscarinic acetylcholine receptor (M2R) to restore cardiac autonomic balance. It also inhibits CYP2C8 and CYP2C9 with IC50 values of 17 µM and 13 µM, respectively.

BAY 2413555 is a first selective positive allosteric modulator of the muscarinic acetylcholine receptor (M2R) to restore cardiac autonomic balance. It also inhibits CYP2C8 and CYP2C9 with IC50 values of 17 µM and 13 µM, respectively.